Last reviewed · How we verify

Ensifentrine Dose 1 — Competitive Intelligence Brief

Ensifentrine Dose 1 (Ensifentrine Dose 1) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR and ENaC inhibitor. Area: Respiratory.

phase 2 CFTR and ENaC inhibitor CFTR and ENaC Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Ensifentrine Dose 1 (Ensifentrine Dose 1) — Verona Pharma Inc. Ensifentrine is a dual inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ensifentrine Dose 1 TARGET Ensifentrine Dose 1 Verona Pharma Inc phase 2 CFTR and ENaC inhibitor CFTR and ENaC

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CFTR and ENaC inhibitor class)

  1. Verona Pharma Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ensifentrine Dose 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/ensifentrine-dose-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: